Get regular updates to your inbox.
Testing positive for self-reactive antibodies causing both neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) — two related autoimmune disorders — is extremely rare, but it appears to manifest more as NMOSD, a study in India suggests. So-called double positivity was found in three of…
An international team of experts has published evidence-based recommendations for how to best treat people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 immunoglobulin G (AQP4-IgG), the most common type of disease-driving antibody. The consensus statements were described in the study “International Delphi…
Eating more oily fish and raw vegetables may decrease a person’s risk of developing neuromyelitis optica spectrum disorder (NMOSD), according to a new study of the autoimmune disease that used genetic data. While most foods reviewed in the study — including beef, bread, cheese, wine, poultry, and also coffee…
The Sumaira Foundation (TSF), a global patient advocacy group focused on neuromyelitis optica spectrum disorder (NMOSD) and a related condition, has presented Tim Walbert, CEO and president of Horizon Therapeutics, its inaugural Global Rare Trailblazer Award. The award was announced in Boston at the foundation’s…
Starting treatment with off-label rituximab soon after neuromyelitis optica spectrum disorder (NMOSD) symptoms begin may prevent long-term disability worsening, a South Korean study suggests. This approach was particularly true for patients who were younger than 50, female, and for those with a severe level of disability before starting rituximab,…
Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…
Brain and spinal cord lesions resolve less often in children with neuromyelitis optica spectrum disorder (NMOSD) than with myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a related disorder, according to a small study. No significant differences in resolving lesions were seen between children with NMOSD and those with multiple…
CCL2, a signaling protein that recruits immune cells to sites of injury, may play a key role in driving the nerve damage that results from antibodies against the aquaporin-4 (AQP4) protein in neuromyelitis optica spectrum disorder (NMOSD), a study suggests. The signaling protein was found to be elevated in…
Out of four markers of nervous system cell injury, blood levels of neurofilament light chain (NfL) were found to best predict disability worsening in people with neuromyelitis optica spectrum disorder (NMOSD), a study showed. Measures of blood NfL levels at the time of an NMOSD attack were the only ones…
Ultomiris (ravulizumab) has been approved by authorities in Japan to prevent relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) positive for antibodies against aquaporin-4 (AQP4). The decision from the Japanese Ministry of Health, Labour and Welfare comes shortly after a similar approval by the European Commission,…
Get regular updates to your inbox.